102 results on '"Divgi, Chaitanya R."'
Search Results
2. A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer
Catalog
Books, media, physical & digital resources
3. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
4. Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
5. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients
6. Targeted α particle immunotherapy for myeloid leukemia
7. Imaging Characterization of Thyroid Nodules
8. Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease
9. American Journal of Nuclear Medicine and Molecular Imaging: Editorial Board (2014) e-Century Publishing Corporation
10. American Journal of Nuclear Medicine and Molecular Imaging: Editorial Board (2012) e-Century Publishing Corporation
11. Longer Duration of Red Blood Cell Storage Induces Progressively Increased Markers of Extravascular Hemolysis and Hepcidin in Autologously Transfused Healthy Volunteers
12. Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease
13. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model
14. Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin
15. In vitro and in vivo characterization of 177Lu‑huA33 : A radioimmunoconjugate against colorectal cancer
16. Bone Marrow Dosimetry Using 124I-PET
17. Preparation and Characterization of l-[5-11C]-Glutamine for Metabolic Imaging of Tumors
18. 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET
19. 124I-huA33 Antibody PET of Colorectal Cancer
20. Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250
21. Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
22. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy
23. Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors
24. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer
25. Optimizing Prostate Cancer Treatment by Combining Local Radiation Therapy with Systemic Vaccination
26. Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).
27. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.
28. Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin.
29. Bone Marrow Dosimetry Using 124I-PET.
30. Preparation and Characterization of L-[5-11C]-Glutamine for Metabolic Imaging of Tumors.
31. 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET.
32. 124I-huA33 Antibody PET of Colorectal Cancer.
33. Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250.
34. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy.
35. Organ and Fetal Absorbed Dose Estimates from 99mTc-Sulfur Colloid Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients.
36. 211At Radioimmunotherapy of Subcutaneous Human Ovarian Cancer Xenografts: Evaluation of Relative Biologic Effectiveness of an α-Emitter In Vivo.
37. Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer.
38. Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases.
39. Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose--Response.
40. Single-Dose Versus Fractionated Radioimmunotherapy: Model Comparisons for Uniform Tumor Dosimetry.
41. Flare on Bone Scintigraphy Following Taxol Chemotherapy for Metastatic Breast Cancer.
42. Modeling and Dosimetry of Monoclonal Antibody M195 (Anti-CD33) in Acute Myelogenous Leukemi.
43. Pharmacokinetic Model of Iodine-131-G250 Antibody in Renal Cell Carcinoma Patients.
44. A Phase IB Trial of Humanized Monoclonal Antibody M195 (Anti-CD33) in Myeloid Leukemia: Specific Targeting Without Immunogenicity
45. Technetium-99m Albumin Scintigraphy in the Diagnosis of Protein-Losing Enteropathy.
46. All of the Above (With Caveats for Each).
47. Jod-Basedow Syndrome Following Oral Iodine and Radioiodinated-Antibody Administration.
48. Correlation of Tumor Radiation-Absorbed Dose with Response Is Easier to Find in Previously Untreated Patients.
49. Nuclear Medicine--The Requisites.
50. Cancer Therapy with Radiolabeled Antibodies.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.